Document Detail

Insulin versus an oral antidiabetic agent as add-on therapy in type 2 diabetes after failure of an oral antidiabetic regimen: a meta-analysis.
MedLine Citation:
PMID:  21602937     Owner:  NLM     Status:  PubMed-not-MEDLINE    
BACKGROUND: Although evidence-based guidelines for the treatment of type 2 diabetes mellitus provide clear recommendations for initial therapy, evidence on an optimal treatment strategy after secondary failure is unclear.
PURPOSE: To compare the efficacy of add-on therapy using basal insulin versus an additional oral antidiabetic agent in patients with type 2 diabetes and secondary failure.
DATA SOURCES: We searched the following electronic databases from inception until June 2007: MEDLINE; EMBASE; Cochrane Central Register of Controlled Trials; Web of Science; Scopus; CINAHL; International Pharmaceutical Abstracts; Academic OneFile; PASCAL; Global Health Database; LILACS; HealthSTAR; PubMed. Reference lists of potentially relevant articles and clinical trial databases were searched, pharmaceutical manufacturers were contacted, and grey literature sources were sought.
STUDY SELECTION: Randomized controlled trials (RCTs) involving subjects with type 2 diabetes with secondary failure who were randomly assigned to receive additional basal insulin therapy (insulin glargine, detemir, or NPH [neutral protamine Hagedorn]) versus another oral antidiabetic agent from any class.
DATA EXTRACTION: Two reviewers independently screened articles, extracted data and assessed methodological quality. Our primary outcome was glycemic control measured by change in glycosylated hemoglobin (Hb(A1C)) and the proportion of subjects achieving a Hb(A1C) value of ≤ 7%.
DATA SYNTHESIS: To compare overall efficacy between the 2 treatment strategies, change in Hb(A1C) was pooled across studies using a random-effects model and weighted mean difference (WMD). Eleven RCTs, involving 757 participants with a median age of 56 and a median known duration of diabetes of 11 years, were included in our analysis. Insulin treatment demonstrated a small but statistically significant improvement in Hb(A1C) compared with the use of an additional oral agent as add-on therapy (WMD -0.17; 95% CI [confidence interval] -0.33 to -0.02).
LIMITATIONS: The use of surrogate outcomes and the short duration of the trials makes it impossible to gain information on long-term patient-oriented outcomes. The overall quality of the studies was low, primarily in view of inadequate blinding.
CONCLUSIONS: Although add-on therapy using injected insulin shows a slight benefit over an additional oral antidiabetic agent, our results indicate that basal insulin therapy and the use of an oral agent as add-on therapy produce comparable results. Non-therapeutic differences must be considered in the choice of treatment strategies. More high-quality studies with adequate safety data using more aggressive insulin titrations are needed.
Jm Gamble; Scot H Simpson; Lauren C Brown; Jeffrey A Johnson
Related Documents :
18252897 - Quantitative trait analysis of type 2 diabetes susceptibility loci identified from whol...
9789717 - Glut1 gene polymorphism in non-insulin-dependent diabetes mellitus: genetic susceptibil...
10078567 - Phylogenetic analysis of mitochondrial dna in type 2 diabetes: maternal history and anc...
19241057 - A common variant in mtnr1b, encoding melatonin receptor 1b, is associated with type 2 d...
7704957 - Ovaries in sexual precocity.
1810997 - Leg ulcers.
Publication Detail:
Type:  Journal Article     Date:  2008-04-26
Journal Detail:
Title:  Open medicine : a peer-reviewed, independent, open-access journal     Volume:  2     ISSN:  1911-2092     ISO Abbreviation:  Open Med     Publication Date:  2008  
Date Detail:
Created Date:  2011-05-23     Completed Date:  2011-07-14     Revised Date:  2011-07-28    
Medline Journal Info:
Nlm Unique ID:  101319172     Medline TA:  Open Med     Country:  Canada    
Other Details:
Languages:  eng     Pagination:  e26-38     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  CD133 positive embryonal rhabdomyosarcoma stem-like cell population is enriched in rhabdospheres.
Next Document:  Retention of provisionally licensed international medical graduates: a historical cohort study of ge...